The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


Published online July 8, 2009
The Journal of Immunology, 2009, 183, 1990 -1996
Copyright © 2009 by The American Association of Immunologists, Inc.
doi:10.4049/jimmunol.0900252

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jimmunol.0900252v1
183/3/1990    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Rygiel, T. P.
Right arrow Articles by Meyaard, L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rygiel, T. P.
Right arrow Articles by Meyaard, L.

Lack of CD200 Enhances Pathological T Cell Responses during Influenza Infection1

Tomasz P. Rygiel2,*, Eva S. K. Rijkers2,*, Talitha de Ruiter*, Ellen H. Stolte*, Martin van der Valk{dagger}, Guus F. Rimmelzwaan{ddagger}, Louis Boon§, Anton M. van Loon, Frank E. Coenjaerts, Robert M. Hoek||, Kiki Tesselaar* and Linde Meyaard3,*

* Department of Immunology, University Medical Center Utrecht, Utrecht, The Netherlands; {dagger} Netherlands Cancer Institute, Amsterdam, The Netherlands; {ddagger} Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands; § Bioceros, Utrecht, The Netherlands; Department of Virology, University Medical Center Utrecht, Utrecht, The Netherlands; || Department of Experimental Immunology, University Medical Center, Amsterdam, The Netherlands

Influenza virus infection can be accompanied by life-threatening immune pathology most likely due to excessive antiviral responses. Inhibitory immune receptors may restrain such overactive immune responses. To study the role of the inhibitory immune receptor CD200R and its ligand CD200 during influenza infection, we challenged wild-type and CD200–/– mice with influenza virus. We found that CD200–/– mice in comparison to wild-type controls when inoculated with influenza virus developed more severe disease, associated with increased lung infiltration and lung endothelium damage. CD200–/– mice did develop adequate adaptive immune responses and were able to control viral load, suggesting that the severe disease was caused by a lack of control of the immune response. Interestingly, development of disease was completely prevented by depletion of T cells before infection, despite dramatically increased viral load, indicating that T cells are essential for the development of disease symptoms. Our data show that lack of CD200-CD200R signaling increases immune pathology during influenza infection, which can be reduced by T cell depletion.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by Grant 015.001.070 from The Netherlands Organization for Scientific Research (NWO) (to E.S.K.R.), Grant 07-0086 from The Association for International Cancer Research (AICR) (to T.R.), and Grant 187 from the VanderEs foundation (to E.H.S.).

2 T.P.R. and E.S.K.R. contributed equally to this work.

3 Address correspondence and reprint requests to Dr. Linde Meyaard, Department of Immunology, University Medical Center Utrecht, Lundlaan 6, Room KC02.085.2, 3584 EA Utrecht, The Netherlands. E-mail address l.meyaard{at}umcutrecht.nl

4 Abbreviations used in this paper: DC, dendritic cell; BAL, bronchoalveolar lavage; NP, nucleoprotein; PD-1, programmed death-1; TCID, tissue culture-infective dose; WT, wild type.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.